<DOC>
	<DOC>NCT01384461</DOC>
	<brief_summary>This observational study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with moderate to severe rheumatoid arthritis. Data will be collected for 12 months from patients initiated on treatment with RoActemra/Actemra (8 mg/kg intravenously every 4 weeks) and methotrexate (weekly dose at the discretion of the physician).</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis RoActemra/Actemra treatment initiated by rheumatologist in an Arthritis Center for (up to 2 months prior to study entry) History of severe allergic or anaphylactic reactions or known hypersensitivity to any component of the drug Active, severe infection or history of recurrent clinically significant infection Pregnancy Treatment with an investigational agent within 4 weeks (or 5 halflives of the investigational agent, whichever is longer) before baseline visit Methotrexate intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>